San Francisco-Based Biotech Company to Close, Liquidate Assets
Third Harmonic Bio, once worth $1 billion, has been developing a treatment for chronic spontaneous urticaria, or hives. San Francisco-based biopharmaceutical company Third Harmonic Bio has decided to shut down operations and liquidate assets, the company announced April 14. Third Harmonic Bio, which began operating in 2019, is a clinical-stage biotech operation focused on treating